Gómez-Arámbula H, Hidalgo-Hurtado A, Rodríguez-Flores R, González-Amaro AM, Garrocho-Rangel A, Pozos-Guillén A. Moxifloxacin versus Clindamycin/Ceftriaxone in the management of odontogenic maxillofacial infectious processes: A preliminary, intrahospital, controlled clinical trial. J Clin Exp Dent. 2015;7(5):e634-9.

doi:10.4317/jced.52627

http://dx.doi.org/doi:10.4317/jced.52627

References

1. Singh M, Kambalimath DH, Gupta KC. Management of odontogenic space infection with microbiology study. J Maxillofac Oral Surg. 2014;13:133-9.
http://dx.doi.org/10.1007/s12663-012-0463-6
PMid:24822004 PMCid:PMC4016404

2. Cachovan G, Nergiz I, Thuss U, Siefert HM, Sobottka I, Oral O, et al. Penetration of moxifloxacin into rat mandibular bone and soft tissue. Acta Odontol Scand. 2009;67:182-6.
http://dx.doi.org/10.1080/00016350902787564
PMid:19306136

3. Walia IS, Borle RM, Mehendiratta D, Yadav AO. Microbiology and antibiotic sensitivity of head and neck space infections of odontogenic origin. J Maxillofac Oral Surg. 2014;13:16-21.
http://dx.doi.org/10.1007/s12663-012-0455-6
PMid:24644391 PMCid:PMC3955478

4. Sobottka I, Wegscheider K, Balzer L, Böger RH, Hallier O, Giersdorf I, et al. Microbiological analysis of a prospective, randomized, double-blind trial comparing moxifloxacin and clindamycin in the treatment of odontogenic infiltrates and abscesses. Antimicrob Agents Chemother. 2012;56:2565-9.
http://dx.doi.org/10.1128/AAC.06428-11
PMid:22354306 PMCid:PMC3346634

5. Limeres J, Tomás I, Álvarez M, Diz P. Empirical antimicrobial therapy for odontogenic infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100:263-4.
http://dx.doi.org/10.1016/j.tripleo.2004.12.019
PMid:16122650

6. Al-Nawas B1, Walter C, Morbach T, Seitner N, Siegel E, Maeurer M, et al. Clinical and microbiological efficacy of moxifloxacin versus amoxicillin/clavulanic acid in severe odontogenic abscesses: a pilot study. Eur J Clin Microbiol Infect Dis. 2009;28:75-82.
http://dx.doi.org/10.1007/s10096-008-0587-2
PMid:18663500

7. Swift JQ, Gulden WS. Antibiotic therapy-managing odontogenic infections. Dent Clin N Am. 2002;46:623-33.
http://dx.doi.org/10.1016/S0011-8532(02)00031-9

PMid:12436820

8. Kuriyama T, Karasawa T, Nakagawa K, Saiki Y, Yamamoto E, Nakamura S. Bacteriologic features and antimicrobial susceptibility in isolates from orofacial odontogenic infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90:600-8.
http://dx.doi.org/10.1067/moe.2000.109639
PMid:11077383

9. Sobottka I, Cachovan G, Stürenburg E, Ahlers MO, Laufs R, Platzer U, et al. In vitro activity of moxifloxacin against bacteria isolated from odontogenic abscesses. Antimicrob Agents Chemother. 2002;46:4019-21.
http://dx.doi.org/10.1128/AAC.46.12.4019-4021.2002
PMid:12435716 PMCid:PMC132736

10. Milazzo I, Blandino G, Musumeci R, Nicoletti G, Lo Bue AM, Speciale A. Antibacterial activity of moxifloxacin against periodontal anaerobic pathogens involved in systemic infections. Int J Antimicrob Agents. 2002;20:451-6.
http://dx.doi.org/10.1016/S0924-8579(02)00190-5

PMid:12458140

11. Tomás I, Alvarez M, Limeres J, Otero JL, Saavedra E, López-Meléndez C, Diz P. In vitro activity of moxifloxacin compared with other antimicrobials against streptococci isolated from iatrogenic oral bacteremia in Spain. Oral Microbiol Immunol. 2004;19:331-5.
http://dx.doi.org/10.1111/j.1399-302x.2004.00167.x
PMid:15327647

12. Cachovan G, Böger RH, Giersdorf I, Hallier O, Streichert T, Haddad M, et al. Comparative efficacy and safety of moxifloxacin and clindamycin in the treatment of odontogenic abscesses and inflammatory infiltrates: a phase II, double-blind, randomized trial. Antimicrob Agents Chemother. 2011;55:1142-7.
http://dx.doi.org/10.1128/AAC.01267-10
PMid:21173173 PMCid:PMC3067083

13. Richards DM, Heel RC, Brogden RN, Speight TM, Avery GS. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1984;27:469-527.
http://dx.doi.org/10.2165/00003495-198427060-00001
PMid:6329638

14. Heit JM, Stevens MR, Jeffords K. Comparison of ceftriaxone with penicillin for antibiotic prophylaxis for compound mandible fractures. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;83:423-6.
http://dx.doi.org/10.1016/S1079-2104(97)90139-6

PMid:9127371

15. Brennan MT, Runyon MS, Batts JJ, Fox PC, Kent ML, Cox TL, et al. Odontogenic signs and symptoms as predictors of odontogenic infection: a clinical trial. J Am Dent Assoc. 2006;137:62-6.
http://dx.doi.org/10.14219/jada.archive.2006.0022
PMid:16457000

16. Pocock SJ. Allocation of patients to treatment in clinical trials. Biometrics. 1979;35:183-197.
http://dx.doi.org/10.2307/2529944
PMid:497334

17. Midolo PD, Tumidge J, Lambert JR, Bell JM. Validation of a modified Kirby-Baur disk diffusion method for metronidazole susceptibility testing of Helicobacter pylori. Diagn Microbiol Infect Dis. 1995;21:135-40.
http://dx.doi.org/10.1016/0732-8893(95)00066-J

PMid:7648834

18. Clinical Laboratory Standards Institute (CLSI). Performance standards for antimicrobial disks susceptibility. Approved Standard, 9th ed. CLSI document M2-A9. Wayne, PA, USA: CLSI; 2006.

19. Chunduri NS, Madasu K, Goteki VR, Karpe T, Reddy H. Evaluation of bacterial spectrum of orofacial infections and their antibiotic susceptibility. J Maxillofac Surg. 2012;2:46-50.
http://dx.doi.org/10.4103/2231-0746.95318

PMid:23482901

20. Sepännen L, Lauhio A, Lindqvist C, Suuronen R, Ratemaa R. Analysis of systemic and local odontogenic infection complications infection complications requiring hospital care. J Infect 2008;57:116-22.
http://dx.doi.org/10.1016/j.jinf.2008.06.002
PMid:18649947

21. Warnke PH, Becker ST, Springer IN, Haerle F, Ullmann U, Russo PA, et al. Penicillin compared with other advanced broad spectrum antibiotics regarding antibacterial activity against oral pathogens isolated from odontogenic abscesses. J Craniomaxillofac Surg 2008;36:462-7.
http://dx.doi.org/10.1016/j.jcms.2008.07.001
PMid:18760616